Immunohistochemistry has been used to assess p53 status in PDAC and other cancers, as the mutated form of p53 protein is known to accumulate in the nucleus of tumour cells and is detectable by immunohistochemistry, whereas the wild-type protein is rapidly degraded36–39. This evidence concerns the gene TP53 and neoplasm.